Back

 

HOSPITAL NAMEPILLS HOSPITAL
DISTRICTCOIMBATORE
ADDRESS70/53, BHARATHI ROAD, LIG COLONY 1, MAHALINGAPURAM, POLLACHI, COIMBATORE - 642 002
HOSPITAL CONTACT NO04259 235757, 9843313609
AVAILABLE SPECIALITIESGENERAL MEDICINE
ENDOCRINE SURGERY
ENDOCRINOLOGY
GENERAL SURGERY
GENITOURINARY SURGERY
MEDICAL GASTROENTEROLOGY
MEDICAL ONCOLOGY
OBSTETRICS AND GYNAECOLOGY
PEDIATRICS
PLASTIC SURGERY
VASCULAR SURGERY

Packages Rate
CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles 3000
CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles 7000
CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles 6000
CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles 2700
CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles 5100
CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles 5100
CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles 5500
CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks 3500
CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles 3200
CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5600
CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle 3000
CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3500
CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) 30500
CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) 11500
CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles 7100
CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year 11500
CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 3000
CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles 5400
CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) 30500
CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, 5000
CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) 11500
CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. 3000
CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) 30500
CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) 30500
CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) 11500
CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles 3800
CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. 6400
CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. 4800
CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. 14500
CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. 16500
CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. 7600
CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. 9000
CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) 14500
CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. 7600
CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 33600
CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles 17900
CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 4900
CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 6300
CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 6100
CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. 14500
CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. 8100
CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). 8500
CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). 8200
CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. 16500
CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. 14900
CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks 3300
CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. 4900
CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles 6500
CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. 5800
CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. 5700
CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles 7700
CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks 3300
CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. 12000
CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles 7100
CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles 4600
CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2500
CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV 25800
CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. 8900
CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. 9700
CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. 5500
CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 7800
CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles 12000
CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles 7100
CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. 25400
CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion 9000
CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation 3100
CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. 1600
CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. 6500
CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV 12000
CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles 7100
CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. 25800
CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks 2000
CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. 3300
CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle 8900
CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks 3000
CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. 13100
CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. 9700
CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. 5500
CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. 12200
CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. 3300
CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV 12000
CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. 7100
CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. 25800
CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. 6100
CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 2000
CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks 8900
CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks 5500
CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. 3100
CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 16700
CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 18700
CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. 5900
CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively 7800
CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. 6900
CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days 25400
CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days 14900
CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. 3100
CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. 1600
CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. 6500
CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. 4000
CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. 6000
CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles 8000
CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months 6500
CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; 30000
CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks 4300
CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. 23700
CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. 5200
CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy 3800
CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. 6100
CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. 1300
CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles 5600
CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV 24200
CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. 40100
CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis 59100
CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) 111505
CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). 8300
CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily 4500
CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. 4500
CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD 6000
CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD 2200
CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD 28500
CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle 56000
CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly 4600
CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. 3500
CM0106-iv-a : VAC and IE cycles 6420
CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. 7600
CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 19400
CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 23200
CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 53700
CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week 84500
CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles 2800
CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles 2400
CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID 5800
CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN 8000
CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 7100
CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 4900
CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 6500
CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only 10000
CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial 9700
CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial 8900
CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial 9900
CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial 8600
CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular 1900
CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular 4300
CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal 270
CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal 1900
CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal 1600
CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 6800
CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6100
CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 6800
CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year 1800
CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles 3800
CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles 5600
CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles 5500
CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles 8300
CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients 7600
CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. 17700
CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. 8200
CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable 10000
CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles 1800
CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 9200
CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 8900
CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV 1800
CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles 4700
CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), 11400
CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses 1800
CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. 8800
CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles 7000
CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles 8700
CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) 10000
CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles 10800
CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles 6500
CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days 2100
CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days 2900
CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days 2000
CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly 1300
CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days 7800
CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks 2200
CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days 6400
CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. 5400
CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. 10000
CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. 6300
CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated 3600
CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg 13500
CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside 19500
CM0125-c : Other Regimen 10000
CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID 2900
CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg 28500
CM0126-c : THYROID CANCER - pazopanib 9500
CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 4400
CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. 4600
CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. 6800
CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. 5900
CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. 5100
CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles 7600
CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. 9300
CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. 3800
CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. 6500
CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day 2100
CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. 3400
CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. 2100
CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks 3800
CM0128-ii-d : Adjuvant Temozolomide 2100
CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles 3800
CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. 2100
CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days 2100
CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally 2100
CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT 4400
CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. 5500
CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. 6600
CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV 9500
CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles 41900
CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; 7900
CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. 7900
CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles 32400
CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles 7900
CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. 26600
CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. 1600
CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; 6000
CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; 5400
CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. 2900
CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles 2000
CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). 4700
CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 2300
CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy 3400
CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy 5300
CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy 3500
CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week 1800
CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. 5300
CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. 6700
CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. 7900
CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU 2000
CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles 6700
CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; 4300
CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 13500
CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles 1800
CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles 6200
CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation 2800
CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles 3900
CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. 2300
CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles 5100
CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0130-a : Pazopanib 19000
CM0130-b : Sunitinib 29000
CM0130-c : Sorafenib 5800
CM0130-d : Other Regimen 10000
CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles 8000
CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles 7200
CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. 3800
CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. 5300
CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles 5800
CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles 5600
CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d 6200
CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. 6800
CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days 5000
CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted 3700
CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV 4100
CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days 3600
CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles 6600
CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks 5000
CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. 6700
CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. 20700
CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. 3600
CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 5300
CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily 3000
CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks 11500
CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks 9200
CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. 10700
CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. 12800
CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks 5100
CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks 14700
CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; 3300
CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks 2900
CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. 10000
CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks 1900
CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks 5900
CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. 3600
CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. 6200
CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. 2400
CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. 7900
CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks 4200
CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks 1700
CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses 4400
CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV 7600
CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0137-vi : Other Regimen 10000
CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy 10000
CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy 11400
CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. 8100
CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy 6800
CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy 6700
CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0158 : UPTO-40% WITH SCALDS (CONSERVATIVE) 20412
CM0159 : UPTO-40% MIXED BURNS (WITH SURGERIES) 29160
CM0160 : UPTO-50% WITH SCALDS (CONSERVATIVE) 36304
CM0161 : UPTO-50% MIXED BURNS ( WITH SURGERIES) 44469
CM0162 : UPTO-60% WITH SCALDS (CONSERVATIVE) 54529
CM0163 : UP TO-60% MIXED BURNS (WITH SURGERIES) 59049
CM0164 : ABOVE 60% MIXED BURNS (WITH SURGERIES) 73629
CM0165 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - MILD 15309
CM0166 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - MODERATE 22599
CM0167 : POST BURN CONTRACTURE FOR FUNCTIONAL IMPROVEMENT (INCLUDING SPLINT / PRESSURE GARMENT / PHYSIOTHERAPY) - SEVERE 28431
CM0168 : PTOSIS 17861
CM0169 : CUP AND BAT EARS 17861
CM0170A : FILARIAL LYMPHOEDEMA -NV SHUNT 10133
CM0170B : FILARIAL LYMPHOEDEMA -REDUCTION SURGERY 17861
CM0171 : HEMIFACIAL ATROPHY 25223
CM0172 : HEMIFACIAL MICROSMIA 36158
CM0173 : LEPROSY RECONSTRUCTIVE SURGERY 21068
CM0174 : TUMOR OF MANDIBLE AND MAXILLA 29233
CM0175 : CORRECTIVE SURGERY FOR CONGENITAL DEFORMITY OF HAND (PER HAND) 19391
CM0176 : PRESSURE SORE RECONSTRUCTIVE SURGERY 32003
CM0177 : ABDOMINAL WALL RECONSTRUCTION INCLUDING POST CANCER EXCISION 31930
CM0178 : LID DEFORMITY CORRECTION (FOLLOWING TRAUMA/BURNS/CONGENITAL) 12247
CM0209 : ACQUIRED HEART DISEASE WITH CONGESTIVE CARDIAC FAILURE 12393
CM0210 : INBORN ERROR OF METABOLISM 29160
CM0211 : HEMOPHAGOCYTIC LYMPHO HISTIOCYTOSIS 21870
CM0212 : HYPOPLASTIC/APLASTIC ANEMIA (FANCONI ANEMIA) 2260
CM0213 : NECROTISING ENTEROCOLITIS - CLINICAL SEPSIS /HYPERBILIRUBINEMIA /NON VENTILATED 18225
CM0214 : VITAMIN D RESISTANT RICKETS 7290
CM0215 : ADRENAL FAILURE INCLUDING PRIMARY ADRENAL FAILURE AND CAH 18225
CM0216 : PRIMARY IMMUNO DEFICIENCY DISORDERS 109350
CM0336 : D V T - IVC FILTER 52743
CM0337 : PERIPHERAL EMBOLECTOMY WITHOUT GRAFT 20048
CM0338 : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL 28978
CM0339 : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE 53946
CM0340 : ARTERIAL EMBOLECTOMY 20594
CM0341 : VASCULAR TUMORS 28832
CM0342 : SMALL ARTERIAL ANEURYSMS - REPAIR 13851
CM0343 : MEDIUM SIZE ARTERIAL ANEURYSMS - REPAIR 33899
CM0344 : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT 53582
CM0345 : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION 50483
CM0346 : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR 33352
CM0347A : AORTO - BILLIAC - BIFEMORAL BYPASS WITH VEIN 57773
CM0347B : AORTO - BILLIAC - BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 67615
CM0348 : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT 68708
CM0349 : FEMORO DISTAL BYPASS WITH VEIN GRAFT 41006
CM0350 : FEMORO DISTAL BYPASS WITH SYNTHETIC GRAFT 57409
CM0351 : AXILLO BRACHIAL BYPASS USING SYNTHETIC GRAFT 45380
CM0352 : BRACHIO - RADIAL BYPASS WITH SYNTHETIC GRAFT 34810
CM0353 : FEMORO- POPLITEAL BYPASS WITH GRAFT 40642
CM0354 : FEMORO- POPLITEAL BYPASS WITHOUT GRAFT 22052
CM0355 : FEMORO ILEAL BYPASS WITH GRAFT 32987
CM0356 : FEMORO ILEAL BYPASS WITHOUT GRAFT 16949
CM0357 : FEMORO FEMORAL BYPASS WITH GRAFT 32623
CM0358 : FEMORO FEMORAL BYPASS WITHOUT GRAFT 17678
CM0359 : AORTO RENAL BYPASS 36268
CM0360 : AORTO MESENTRIC BYPASS 36268
CM0361 : CAROTID SUBCLAVIAN ARTERY BYPASS WITH SYNTHETIC GRAFT 54128
CM0362 : AXILLO AXILLARY BYPASS WITH SYNTHETIC GRAFT 37361
CM0363 : SUBCLAVIAN SUBCLAVIAN BYPASS WITH SYNTHETIC GRAFT 38090
CM0364 : CAROTID BODY TUMOR - EXCISION 31566
CM0365 : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT 67250
CM0366 : SURGERY WITHOUT GRAFT FOR ARTERIAL INJURIES OR VENOUS INJURIES 7837
CM0367 : VASCULAR INJURY IN UPPER LIMBS - AXILLARY, BRANCHIAL, RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 24786
CM0368 : MAJOR VASCULAR INJURY -REPAIR - LOWER LIMBS(INCLUDING FOOT) 30436
CM0369 : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (INCLUDING FOOT) 13304
CM0370 : SURGERY WITH VEIN GRAFT 12029
CM0371 : WITH PROSTHETIC GRAFT 29160
CM0372 : NECK VASCULAR INJURY - CAROTID VESSELS 66157
CM0373 : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS 66157
CM0374 : THORACIC VASCULAR INJURIES 66157
CM0375 : VARICOSE VEINS RFA FOR B/L 27338
CM0376 : COVERED STENT PLACEMENT FOR ANEURSYM / MURAL THROMBOSIS- Aorto-illiac 104794
CM0377A : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - STK 36268
CM0377B : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (CATHETER DIRECTED THROMBOLYSIS) - RTPA 53035
CM0378 : BRACHIO - BASILIC TRANSPOSITION FOR HEMODIALYSIS ACCESS 16038
CM0379 : VERTEBRAL ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 51577
CM0380A : END ARTERECTOMY FOR PERIPHERAL ARTERIES 25515
CM0380B : END ARTERECTOMY FOR PERIPHERAL ARTERIES / PATCH CLOSURE 29160
CM0381 : END ARTERECTOMY FOR LARGE ARTERIES 36268
CM0382 : THROMBIN INJECTION UNDER DUPLEX GUIDANCE FOR PSEUDOANEURYSM 13851
CM0383 : PSEUDOANEURYSM MANAGEMENT WITH USG COMPRESSION THERAPY 7108
CM0384 : PSEUDOANEURYSM LIGATION 25333
CM0385 : PROFUNDA PLASTY 22052
CM0388 : SYSTEMIC THROMBOLYSIS IN PERIPHERAL ARTERY DISEASE 10935
CM0389A : REDO BYPASS AFTER GRAFT THROMBOSIS - VEIN GRAFT 36268
CM0389B : REDO BYPASS AFTER GRAFT THROMBOSIS - SYNTHETIC GRAFT 41371
CM0390A : ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 45927
CM0390B : ENDOVASCULAR AORTIC REPAIR - WITH PATCH 71624
CM0391A : THORACIC ENDOVASCULAR AORTIC REPAIR - WITHOUT PATCH 66886
CM0391B : THORACIC ENDOVASCULAR AORTIC REPAIR - WITH PATCH 86933
CM0392 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL 111537
CM0393 : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL 142520
CM0394 : TUMOR RESECTION WITH VASCULAR RECONSTRUCTION 48879
CM0395 : GRAFT THROMBECTOMY BYPASS / AV ACCESS SURGERY 15491
CM0396 : SARTORIUS/ GRACILIS MUSCLE FLAP COVER FOR VASCULAR COVER 21323
CM0471 : ECLAMPSIA WITH COMPLICATIONS REQUIRING VENTILATORY SUPPORT 20230
CM0472 : ECLAMPSIA WITH COMPLICATIONS & HELLP SYNDROME 16949
CM0473 : ABRUPTIO-PLACENTA WITH OUT COAGULATION DEFECTS (DIC) 14252
CM0474 : ABRUPTIO-PLACENTA WITH COAGULATION DEFECTS (DIC) 18626
CM0477 : SLINGS WITH MESH REPAIR FOR PROLAPSE 13158
CM0478A : VAULT PROLAPSE ABDOMINAL REPAIR WITHOUT MESH 11700
CM0478B : VAULT PROLAPSE ABDOMINAL REPAIR WITH MESH 12429
CM0480 : LAPAROSCOPIC MYOMECTOMY 15345
CM0481 A : RECANALISATION ANY TYPE- open 10607
CM0481 B : RECANALISATION ANY TYPE- lap 13887
CM0482 : STAGING LAPROTOMY FOR OVARIAN AND UTERINE CA 19683
CM0484 : LAPAROSCOPIC SLING OPERATIONS 17168
CM0485A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY 13887
CM0485B : PPH SURGICAL MANAGEMENT -LIGATION/ EMBOLIZATION 11700
CM0501 : ACUTE BRONCHITIS AND PNEUMONIA WITH RESPIRATORY FAILURE 29160
CM0502 : REQUIRING VENTILATORY SUPPORT -OP POISIONING / METABOLIC COMA/SCORPION STING/ SNAKE BITE / BITES & STINGS - MAX 7 DAYS 22050
CM0506 : CORROSIVE OESOPHAGEAL INJURY 20521
CM0507 : ACUTE PANCREATITIS WITH PSEUDOCYST (INFECTED) 21870
CM0508 : CHRONIC PANCREATITIS WITH SEVERE PAIN I) SEMS- SELF EXPANDABLE METALLIC STENT FOR BILIARY OBSTRUCTION (OBSTRUCTIVE JAUNDICE)- MALIGNANT/BENIGN 51285
CM0509 : CHRONIC PANCREATITIS WITH SEVERE PAIN- II) ENDOSCOPIC PANCREATIC SPINCTEROTOMY AND /OR PANCREATIC DUCT STENTING 12211
CM0510 : CHRONIC PANCREATITIS WITH SEVERE PAIN-PANCREATIC DUCT STENTING- PANCRETIC DUCT LEAKS, PSEUDOCYST OF PANCREAS, PANCREATIC STRICTURE, PANCREATIC STONE DISEASE 12211
CM0511 : NON VARICEAL BLEED- HEATER PROBE (UPPER & LOWER GI BLEED) INCLUDES GAVE, ULCER, RADIATION PROCTITIS/COLITIS, POST POLYPECTOMY BLEED, DIEULAFOYS LESION, ANGIODYSPLASIA,MALLORY WEISS TEAR. 11992
CM0538 : GROWTH HORMONE FOR HYPOPITUTARISM 200000
CM0539 : PITUITARY - ACROMEGALY 16731
CM0540 : CUSHINGS SYNDROME 56169
CM0541 A : DELAYED PUBERTY HYPOGONADISM (EX.TURNERS SYND, KLEINFELTER SYND) - MALES 11117
CM0541 B : DELAYED PUBERTY HYPOGONADISM (EX.TURNERS SYND, KLEINFELTER SYND) - FEMALES 16147
CM0573 A : CYSTOLITHOTRIPSY 10206
CM0573 B : CYSTOLITHOTRIPSY - LASER LITHOTRIPSY 12393
CM0573 C : RETROGRADE INTRARENAL SURGERY 20412
CM0574 : PERCUTANEOUS NEPHROLITHOTOMY 22599
CM0575 : EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY 14580
CM0576 : URETERO RENOSCOPIC LITHOTRIPSY 16038
CM0577 : SINGLE STAGE URETHROPLASTY FOR STRICTURE URETHRA 33534
CM0578 : BUCCAL MUCOSAL GRAFT- URETHROPLASTY 25515
CM0579 A : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE I 18225
CM0579 B : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - STAGE II 25515
CM0580 : DOUBLE STAGE URETHROPLASTY FOR STRICTURE URETHRA - RECONSTRUCTION PROCEDURE 25515
CM0581 : ANATROPHIC PEYLOLITHOTOMY FOR STAGHORN CALCULUS 32805
CM0582 A : RENAL CYST EXCISION - LAP 18225
CM0582 B : RENAL CYST EXCISION - OPEN 18225
CM0583 A : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - LAP 29160
CM0583 B : NEPHRECTOMY PYONEPHROSIS/XANTHO GRANULOMATOUS PYELONEPHRITIS - OPEN 29160
CM0584 : ENDOSCOPE REMOVAL OF STONE IN BLADDER 10206
CM0585 : URETERIC INJURY REPAIR 21870
CM0586 : BLADDER INJURY REPAIR 21870
CM0587 : URETERIC REIMPLANTATION 29160
CM0588 : VESICO VAGINAL FISTULA 21870
CM0589 : CLOSURE OF URETHRAL FISTULA 16038
CM0590 : OPTICAL URETHROTOMY 18225
CM0591 : PERINEAL URETHROSTOMY 14580
CM0592 : ANDERSON HYNES PYELOPLASTY 25515
CM0593 A : CAECO CYSTOPLASTY / AUGMENTATION - CYSTOPLASTY 23328
CM0593 B : BLADDER NECK INCISION (BNI) 14580
CM0594 : SUPRA PUBLIC CYSTOSTOMY 5832
CM0595 : DIVERTICULECTOMY /PERSISTENT URACHUS 14580
CM0596 : URACHAL SINUS/TUMOR / EXCISION 14580
CM0597 : INCONTINENCE URINE- (MALE)/ (FEMALE-INCLUDING CYSTOSCOPY OTIS URETHROTOMY) 10935
CM0598 : TRANSURETHRAL RESECTION OF PROSTATE (TURP) 19683
CM0599 : TURP WITH CYSTOLITHOTRIPSY 20412
CM0600 : CHORDEE CORECTION 10935
CM0615-II : CAROTID EMBOLECTOMY 35612
CM0616-II : PULMONARY EMBOLECTOMY WITH IVC FILTER 53582
CM0617-II : RENAL ANGIOPLASTY 41371
CM0618-II : VERTERBRAL ANGIOPLASTY 45745
CM0624-II : WERTHEIMS / RADICAL HYSTERECTOMY 20813
CM0626 A : DENGUE SHOCK SYNDROME -(ADULT/PAEDIATRICS) 16038
CM0626 B : DENGUE HEMORRHAGIC FEVER -(ADULT/PAEDIATRICS) 13122
CM0628-I : NEPHROSTOMY 5832
CM0628-II : NEPHROSTOMY 5832
CM0629-II : OBSCURE/ NON VARICEAL BLEED- CLIPPING / ARGON PLASMA COAGULATION/ INJECTION/CONSERVATIVE 33643
CM0630 A-II : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY 11664
CM0631A-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY ) 8748
CM0631B-II : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY / INTERNAL ORGAN INVOLVEMENT REQUIRING INTRAVENOUS IMMUNOGLOBULIN/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ PNEUMOCOCCAL VACCINATION) 145800
CM0635-II : OPEN PROSTATECTOMY 21870
CM0636-II : RADICAL PROSTATECTOMY 36450
CM0640 : USG GUIDED MAJOR PROCEDURES ( EG. LIVER ABSCESS,POST OP COLLECTIONS)DRAINAGE PIGTAIL INSERTION 6926
CM0641A-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION Solid organs) 21141
CM0641B-I : USG GUIDED MAJOR PROCEDURES (RF ABLATION other organs ) 18225
CM0641C-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION Solid organs) 15674
CM0641D-I : USG GUIDED MAJOR PROCEDURES (ETHANOL ABLATION other organs) 28431
CM0642A-I : USG GUIDED MINOR PROCEDURES (FNAC & BIPOSY) 1094
CM0642B-I : USG GUIDED MINOR PROCEDURES (SINOGRAPHY) 1458
CM0642C-I : USG GUIDED MINOR PROCEDURES (TAPPING) 1094
CM0643-II : RENAL ARTERY EMBOLIZATION WITH MULTIPLE COILS AND MICRO CATHETER 69437
CM0644-II : EMBOLIZATION OF AV MALFORMATION OF PERIPHERAL EXTREMITY, CRANIOFACIAL AND VISCERAL PER SITTING 48661
CM0645-II : GASTROINTESTINAL VISCERAL ARTERIAL EMBOLIZATION IN UPPER AND LOWER GASTROINTESTINAL BLEEDING WITH MICROCATHETER 55586
CM0646-II : BRONCHIAL ARTERY EMBOLIZATION IN HEMOPTYSIS USING PVA AND MICRO CATHETER 40642
CM0647-II : EMBOLIZATION OF POSTOPERATIVE/ POST TRAUMATIC BLEEDING 59596
CM0648-II : UTERINE ARTERY EMBOLIZATION IN SEVERE MENORRHAGIA SECONDARY TO PPH/UTERINE FIBROIDS / AVM 38455
CM0649-II : PREOPERATIVE PORTAL VEIN EMBOLIZATION FOR LIVER TUMORS 51212
CM0650-II : EMBOLIZATION OF PULMONARY AV MALFORMATION 53399
CM0652-II : EMBOLIZATION OF CARATICO-CAVERNOUS FISTULA 67615
CM0653-II : PLAIN SIMPLE COILING OF ANEURYSM 34810
CM0654-II : BRAIN AVM EMBOLIZATION 71260
CM0655-II : TUMOR EMBOLIZATION 61054
CM0656-II : PERIPHERAL AVM EMBOLIZATION 55951
CM0657-II : TRANS ARTERIAL CHEMOEMBOLIZATION 66886
CM0658-II : HEAD AND NECK TUMOR EMBOLIZATION 53764
CM0659-II : PSEUDOANEURYSM EMBOLIZATION 33352
CM0660-II : PROSTATIC ARTERY EMBOLIZATION 31529
CM0668-II : SUPERFICIAL FEMORAL ARTERY ANGIOPLASTY ANY STENTING 78185
CM0669-II : FISTULA SALVAGE ANGIOPLASTY 53399
CM0670-II : CAROTID ARTERY STENTING WITH EMBOLIC PROTECTION DEVICE 96775
CM0671-II : ILIAC / IVC STENTING / HIGH END VASCULAR REVASCULARISATION PROCEDURE 80372
CM0672-II : VENOUS / POLY TETRA FLUORO ETHYLENE PATCH ANGIOPLASTY 41735
CM0673-II : SUBCLAVIAN, ILIAC, SUPERFICIAL FEMORAL ARTERY STENTING EACH WITH ONE STENT 76363
CM0674-II : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA 67979
CM0675-II : MESENTERIC ARTERY ANGIOPLASTY & STENTING IN ACUTE & CHRONIC MESENTERIC ISCHEMIA - SINGLE STENT 67979
CM0676-II : CENTRAL VENOUS STENTING FOR CENTRAL VENOUS OCCLUSION (BRACHIOCEPHALIC, SUBCLAVIAN VEIN AND SUP VENA CAVA) SINGLE METALLIC STENT 71624
CM0679-II : PERIPHERAL STENT GRAFT FOR PERIPHERAL ANEURYSMS AND AV FISTULA 89849
CM0680-II : PERIPHERAL ANGIOPLASTY 42464
CM0681-II : PERIPHERAL ANGIOPLASTY AND STENTING 46109
CM0682-II : SVC ANGIOPLASTY AND STENTING 76910
CM0683-II : IVC ANGIOPLASTY 46292
CM0684-II : IVC ANGIOPLASTY AND STENTING 79826
CM0685-II : BELOW KNEE ANGIOPLASTY 38819
CM0686-II : SUBCLAVIAN ANGIOPLASTY STENTING 79279
CM0687-II : RENAL ANGIOPLASTY STENTING 43558
CM0689-III : HEPATIC VEIN ANGIOPLASTY AND STENTING 38455
CM0690-II : CENTRAL VEIN STENOSIS ANGIOPLASTY 76545
CM0692-II : ACUTE STROKE THROMBOLYSIS (R TPA ) 54857
CM0693-II : INFERIOR VENA CAVA FILTER PLACEMENT 57227
CM0694-II : BILIARY DRAINAGE PROCEDURES/ERCP - EXTERNAL DRAINAGE AND STENT PLACEMENT - METALLIC BILIARY STENT / POST OP BILIARY STRICTURE/LEAK/CHOLANGITIS/BILIARY PANCREATITIS/CHOLEDOCHAL CYST/BILE DUCT STONES 68125
CM0695-II : CAROTID STENTING SINGLE STENT WITH EMBOLIC PROTECTION DEVICE 82195
CM0704 : RECONSTRUCTIVE MICRO SURGERY - REPLANTATION OF HAND, FINGER, THUMB, ARM, SCALP ETC 37033
CM0705 : RECONSTRUCTIVE MICRO SURGERY -FREE TISSUE TRANSFER 49499
CM0706-II : EXCISION OF LINGUAL THYROID 14981
CM0707-I : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS 40788
CM0707-II : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS 40788
CM0709 A-I : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 32805
CM0709 A-III : LAP NEPHRECTOMY SIMPLE/HEMI/PARTIAL. 32805
CM0709 B-I : LAP NEPHRECTOMY-RADICAL 32805
CM0709 B-III : LAP NEPHRECTOMY-RADICAL 32805
CM0710 A-I : NEPHROURETERECTOMY OPEN 29160
CM0710 A-II : NEPHROURETERECTOMY OPEN 29160
CM0710 B-I : NEPHROURETERECTOMY LAP 29160
CM0710 B-II : NEPHROURETERECTOMY LAP 29160
CM0713-I : TRACHEOSTOMY 3681
CM0714-I : THOROCOSTOMY 31639
CM0715 : CLEFT LIP 11737
CM0716 : CLEFT PALATE 14653
CM0717 : SYNDACTYLY OF HAND FOR EACH HAND 19391
CM0718A : MICROTIA/ANOTIA - STAGE 1 18517
CM0718B : MICROTIA/ANOTIA - STAGE 2 12830
CM0719 : TM JOINT ANKYLOSIS 29160
CM0720 : RECONSTRUCTIVE MICRO SURGERY -BRACHIAL PLEXUS SURGERY 18225
CM0721 : RECONSTRUCTIVE BREAST SURGERY FOLLOWING CANCER EXCISION, REDUCTION, AUGMENTATION 29452
CM0722-III : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA 14616
CM0725-I : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 17970
CM0725-II : SKIN TUMOR/SOFT TISSUE/BONE TUMORS - EXCISION / AMPUTATION/RESECTION WITH RECONSTRUCTION 17970
CM0730 A-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 29160
CM0730 A-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 29160
CM0730 A-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L OPEN 29160
CM0730 B-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 29160
CM0730 B-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 29160
CM0730 B-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - U/L LAP 29160
CM0730 C-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 40095
CM0730 C-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 40095
CM0730 C-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L OPEN 40095
CM0730 D-I : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 40095
CM0730 D-II : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 40095
CM0730 D-III : URETERIC REIMPLANTATIONS/MEGA URETER OBSTRUCTIVE /REFLUXING - B/L LAP 40095
CM0731-I : HYPOSPADIAS 21870
CM0731-II : HYPOSPADIAS 21870
CM0732-I : EPISPADIAS 30618
CM0732-II : EPISPADIAS 30618
CM0733-I : TORSION TESTIS 18225
CM0733-II : TORSION TESTIS 18225
CM0734-I : URETEROCELE SURGERY 21870
CM0734-II : URETEROCELE SURGERY 21870
CM0735 A-I : OPEN CHOLECYSTECTOMY- RADICAL WITH OR WITHOUT CBD EXPLORATION 36450
CM0735 B-I : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 16038
CM0735 B-II : OPEN CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 16038
CM0736 A-I : LAP CHOLECYSTECTOMY- RADICAL WITH /WITHOUT CBD EXPLORATION 36450
CM0736 B-I : LAP CHOLECYSTECTOMY- ANY TYPE/ CBD EXPLORATION 16038
CM0737-I : LAP CHOLECYSTOSTOMY WITH /WITHOUT EXPLORATION CBD 16038
CM0738-I : OPEN CHOLECYSTOSTOMY 14580
CM0739-II : GASTRECTOMY ANY TYPE - ANY CAUSE 29051
CM0740-II : GASTRECTOMY ANY TYPE - ANY CAUSE WITH LYMPHADENECTOMY 35612
CM0743-II : ANTERIOR RESECTION 37070
CM0744-A-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH 17897
CM0744-B-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH /ILEOSTOMY 35757
CM0744-C-II : SEGMENTAL RESECTION/WEDGE RESECTION OF STOMACH/ WITH STAPLED ANASTOMOSIS 54347
CM0745-II : ABDOMINOPERINIAL RESECTION 28686
CM0746A-I : SPLENECTOMY WITHOUT DEVASCULARISATION -TRAUMATIC 25515
CM0749A-II : NECK DISSECTION ANY TYPE - WITH WIDE EXCISION (INCLUDING MALIGNANCY) 22125
CM0749B-II : NECK DISSECTION ANY TYPE - WITHOUT WIDE EXCISION (INCLUDING MALIGNANCY) 14835
CM0750-A-II : NECK DISSECTION ANY TYPE - WITHOUT RECONSTRUCTION (INCLUDING MALIGNANCY) 18845
CM0750-B-II : NECK DISSECTION ANY TYPE - WITH RECONSTRUCTION (INCLUDING MALIGNANCY) 25406
CM0751-IV : HEMIMANDIBULECTOMY 18334
CM0752-IV : MARGINAL MANDIBULECTOMY 16366
CM0753-IV : SEGMENTAL MANDIBULECTOMY 16366
CM0754 : LEIOMYOMA EXCISION 8748
CM0756 : SURGERIES FOR ENTERO CUTANEOUS FISTULA 29160
CM0757 : INCISIONAL HERNIA REPAIR WITHOUT MESH 14580
CM0758 : INCISIONAL HERNIA REPAIR WITH MESH 18225
CM0759B-i : CRANIOSYNOSTOSIS - STRIP CRANIECTOMY 14580
CM0759B-ii : CRANIOSYNOSTOSIS - ORBITO FACIAL ADVANCEMENT 10935
CM0759B-iii : CRANIOSYNOSTOSIS - PLASTIC SURGICAL CORRECTION 10935
CM0760-I : LIVER ABSCESS - OPEN DRAINAGE 13122
CM0763A-I : RECTAL PROLAPSE - THEIRSCH WIRING 10935
CM0763B-I : RECTAL PROLAPSE - DEBULKING 18954
CM0763C-I : RECTAL PROLAPSE - LAPAROSCOPIC RECTOPEXY 18954
CM0770 A-III : TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 30618
CM0770 B-III : SUB TOTAL COLECTOMY - OPEN/ LAPROSCOPIC -ANY CAUSE 24057
CM0771-III : WHIPPLES ANY TYPE 60143
CM0772A-I : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 25515
CM0772A-III : OPEN CYSTECTOMY(/PARTIAL/ COMPLETE) WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 25515
CM0772B-I : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 32805
CM0772B-III : OPEN CYSTECTOMY(RADICAL )WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 32805
CM0773 A-I : LAPAROSCOPIC CYSTECTOMY [PARTIAL / COMPLETE] WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 25515
CM0773 B-I : LAPAROSCOPIC CYSTECTOMY [RADICAL ]WITH OR WITHOUT DRAINAGE PROCEDURES - ANY CAUSE 32805
CM0774 : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 14616
CM0775-II : SALPINGO OOPHORECTOMY U/L OR B/L- FOR CA 18480
CM0776-II : MASTECTOMY ANY TYPE 14580
CM0777-A-II : MASTECTOMY ANY TYPE WITH AXILLARY DISSECTION 18225
CM0777-B-II : MASTECTOMY ANY TYPE WITH SENTINAL NODE EXPLORATION 18225
CM0778-A-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST -BENIGN 3572
CM0778-B-II : WIDE EXICISION/ LUMPECTOMY - TUMORS OF BREAST (MALIGNANT) 4739
CM0785-II : METASTATECTOMY SOLITARY OR MULTIPLE - ANY CAUSE 27228
CM0786-A-II : OPERATIONS OF ADRENAL GLAND - U/L( ANY CAUSE) 18189
CM0786-B-II : OPERATIONS OF ADRENAL GLAND - B/L ( ANY CAUSE) 32914
CM0795-I : PARATHYROIDECTOMY - ANY TYPE 18225
CM0795-II : PARATHYROIDECTOMY - ANY TYPE 18225
CM0796-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - SMALL INTESTINE- ANY CAUSE 29160
CM0797-I : RESECTION AND ANASTOMOSIS /SEGMENTAL RESECTION - LARGE INTESTINE- ANY CAUSE 32805
CM0798-I : GASTROSTOMY/FEEDING GASTROSTOMY/PERCUTANEOUS ENDOSCOPIC GASTROSTOMY 14580
CM0799-I : OESOPHAGOSTOMY 18225
CM0800-I : JEJUNOSTOMY / FEEDING JEJUNOSTOMY 14580
CM0801-I : GASTROJEJUNOSTOMY 18225
CM0802-I : ILEOSTOMY 14580
CM0803 A-I : ILEOTRANSVERSE COLOSTOMY 18225
CM0803 B-I : COLOSTOMY 14580
CM0804-I : HARTMANNS PROCEDURE WITH COLOSTOMY- ANY CAUSE 32805
CM0805-I : CLOSURE OF GASTROSTOMY/ILEOSTOMY/COLOSTOMY / JEJUNOSTOMY / GASTROJEJUNOSTOMY / ILEOTRANSVERSE COLOSTOMY / OESOPHAGOSTOMY 14580
CM0806-I : RESECTION OF RETRO PERITONEAL TUMORS 32477
CM0808A : URINARY DIVERSION PROCEDURES ( INCLUDING PERCUTANEOUS / ANTEGRADE/RETROGRADE URETERIC STENTING ) 21870
CM0808B : URINARY DIVERSION PROCEDURES ( NEPHROSTOMY) 5832
CM0809 : SUPRA PUBIC CYSTOSTOMY 5832
CM0810-II : INTERCOSTAL DRAINAGE 2989
CM0811 : CRYOTHERAPY FOR ALL LESIONS 16585
CM0812A-i : NERVE RECONSTRUCTION ( WITH NERVE GRAFT ) 25515
CM0812A-ii : NERVE REPAIR NEUROLYSIS 14580
CM0812A-iii : NERVE REPAIR NERVE SUTURING 14580
CM0812B-i : PERIPHERAL NERVE REPAIR 14580
CM0812B-ii : PERIPHERAL NERVE RECONSTRUCTION ( WITH NERVE GRAFT ) 25515
CM0812B-iii : TENDON REPAIR 7290
CM0812B-iv : TENDON RECONSTRUCTION ( WITH TENDON GRAFT) 14580
CM0813 : VAGINAL ATRESIA - (INCLUDING MC INDO-S REPAIR / PLASTIC SURGICAL REPAIR) 21323
CM0814-I : VASCULAR MALFORMATIONS- (INCLUDING SCLEROTHERAPY/ REDUCTION SURGERY) 19136
CM0814-II : VASCULAR MALFORMATIONS- (INCLUDING SCLEROTHERAPY/ REDUCTION SURGERY) 19136
CM0815A : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - MILD 18990
CM0815B : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - MODERATE 25187
CM0815C : RECONSTRUCTIVE UPPER LIMB /HAND/LOWER LIMB/FOOT SURGERY FOLLOWING INFECTION, TRAUMA, BURNS, TUMORS/ MALIGNANCY, DEVELOPMENTAL INCLUDING DIABETIC FOOT - SEVERE 28103
CM0816A : FLAP SURGERIES CUTANEOUS- FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT 18225
CM0816B : MYOCUTANEOUS - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT 25880
CM0816C : OSTEOCUTANEOUS - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT 33170
CM0816D : MICROSURGICAL FREE FLAP SPLIT THICKNESS GRAFT - FOR UPPER LIMB/HAND/LOWER LIMB/FOOT /AFTER FRACTURE FIXATION / ELETRICAL BURNS WITH OR WITHOUT VITALS EXPOSED/ ULCER/FOLLOWING TRAUMA/BURNS/ INFECTION/MALIGNANCY /DEVELOPMENTAL INCLUDING DIABETIC FOOT 49499
CM0817 : POST BURN HYPERTROPHY SURGERY/SCAR REVISION SURGERY 18152
CM0818 : RECONSTRUCTION USING TISSUE EXPANDER (POST TRAUMATIC/POST BURNS) REQUIRES MULTIPLE SITTINGS 40751
CM0819 : FLAP SURGERIES WITH BONE GRAFTING 18954
CM0820-I : AMPUTATION OF ANY SITE / ANY CAUSE WITHOUT PROSTHESIS (except fingers, toes and small joints) 18225
CM0821-I : AMPUTATION OF ANY SITE / ANY CAUSE WITH CUSTOM MADE PROSTHESIS (except fingers, toes and small joints) 100000
CM0822 A-I : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT 437
CM0822 A-II : SOFT TISSUE INJURY - LACERATION (SUTURING) /WOUND DEBRIDEMENT 437
CM0822 B-I : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] 3645
CM0822 B-II : SOFT TISSUE INJURY - DEEP WOUND [NERVE/TENDON REPAIR] 3645
CM0823 : OPERATIONS FOR BRACHIAL PLEXUS (multiple sitting - max 3) 21870
CM0825A : POLYTRAUMA/HEAD INJURY MINOR (only lacerations less than 10 cm) 1823
CM0825B : POLYTRAUMA/HEAD INJURY MINOR (deep / pitted wound exposing scalp/ bone requiring debridement and suturing) 5103
CM0826 : POLYTRAUMA/HEAD INJURY MAJOR (with fractures, intracranial bleeding) 18225
CM0827-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - NON VENTILATED 29160
CM0828-I : SEVERE MYOCARDITIS/CONGENITAL HEART DISEASE PRESENTING WITH OR WITHOUT / INFECTION / FAILURE / CARDIOGENIC SHOCK / SEPTIC SHOCK / INFECTIVE ENDOCARDITIS/ CYANOTIC SPELL - VENTILATED 36450
CM0829-I : STATUS EPILEPTICUS WITH MECHANICAL VENTILATION -(ADULT/PAEDIATRIC ) 29160
CM0830 : DIABETIC KETOACIDOSIS - TYPE I / TYPE II 21870
CM0831-I : CHRONIC RENAL FAILURE WITH HEMODIALYSIS/ERYTHROPOIETIN / IRON 12502
CM0832-I : ACUTE RENAL FAILURE WITHOUT HEMODIALYSIS/ERYTHROPOIETIN / IRON 7071
CM0833-I : ACUTE RENAL FAILURE WITH HEMODIALYSIS/ ERYTHROPOIETIN / IRON 8238
CM0834-I : ACUTE RENAL FAILURE / CRF WITH VENTILATOR CARE 19464
CM0835A-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY-SCUF & SLED 41553
CM0835B-I : ACUTE RENAL FAILURE / CRF - CONTINUOUS RENAL REPLACEMENT THERAPY - CVVH/CVVHD 56133
CM0837-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - NON VENTILATED 21870
CM0838-I : PYOGENIC /TB /VIRAL/ FUNGAL -MENINGITIS/ MENINGOENCEPHALITIS - WITH VENTILATORY SUPPORT 36450
CM0839-I : NEURO TUBERCULOSIS/NEUROCYSTICERCOSIS/ TUBERCULOMA 8748
CM0840 A : IDIPOPATHIC THROMBOCYTOPENIC PURPURA 29160
CM0840 B : TTP 43740
CM0841 A : ANY COAGULATION DISORDERS 36450
CM0841 B : DIC 18225
CM0842 : ECMO - EXTRACORPOREAL MEMBRANE OXYGENATION 180000
CM0843A : MULTI SYSTEM ORGAN FAILURE- ARDS WITHOUT DIC(BLOOD PRODUCTS) 66087
CM0843B : MULTI SYSTEM ORGAN FAILURE- ARDS WITH DIC(BLOOD PRODUCTS) 90387
CM0844 : ENTERIC ENCEPHALOPATHY 14740
CM0845 : LEPTOSPIROSIS WITH HEPATIC INVOLVEMENT 14507
CM0846 : SUBMERSION INJURY WITH VENTILATORY SUPPORT 19683
CM0847 : ARDS WITH VENTILATORY SUPPORT 61272
CM0848-I : RESPIRATORY FAILURE OF ANY CAUSE REQUIRING HIGH FREQUENCY VENTILATION 40970
CM0854 A-I : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 8748
CM0854 A-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY U/L 8748
CM0855 B-II : ORCHIDECTOMY /HIGH ORCHIDECTOMY B/L 10935
CM0877 : CAROTID ENDARTERECTOMY 41006
CM0878-I : PELVIC FLOOR RECONSTRUCTION WITH MESH 22417
CM0878-II : PELVIC FLOOR RECONSTRUCTION WITH MESH 22417
CM0879-I : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 15564
CM0879-II : LAPAROSCOPIC / LAPROTOMY - ECTOPIC RESECTION 15564
CM0880 : LAPAROSCOPIC ADHESOLYSIS 14616
CM0881 A-I : THALASSEMIA MAJOR /HAEMOGLOBINOPATHIES/ CHELATION THERAPY 87480
CM0881 B-I : SICKLE CELL ANAEMIA 3645
CM0882-I : INTERSTITAL LUNG DISEASE 21360
CM0883-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - BANDING 7436
CM0884-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - SCLEROTHERAPY 5540
CM0885-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - DEVASCULARISATION 29160
CM0886-I : OESOPHAGEAL VARICES /GASTRIC VARICES/PESUDO ANEURYSM - GLUE INJECTION 5540
CM0887-I : END STAGE RENAL DISEASE 10315
CM0888-I : GULLAIN BARRE SYNDROME 72900
CM0889-I : OPTIC NEURITIS 7290
CM0891-I : MYASTHENIA GRAVIS 10935
CM0892 : MANAGEMENT OF COMA 21928
CM0895 : HYPER OSMOLAR NON-KETOTIC COMA 21870
CM0896 : OPERATION FOR HYDATID CYST OF LIVER 25515
CM0897-I : HEPATO CELLULAR CARCINOMA (ADVANCED) RADIO FREQUENCY ABLATION 21688
CM0898 : COLONIC PULL THOROUGH /COLOPLASTY/ ABDOMINAL RESECTION 36450
CM0899-I : OESOPHAGECTOMY ANY TYPE INCLUDING (TRANS HIATAL / TRANS THORACIC WITH GASTRIC PULL UP) 47385
CM0900 : OESOPHAGO- GASTRECTOMY 58320
CM0901 : ACHALASIA CARDIA -SURGICAL CORRECTION 21870
CM0902-I : ACHALASIA CARDIA - LAP SURGICAL CORRECTION ( INCLUDING HELLERS MYOTOMY) 21870
CM0903 : ACHALASIA CARDIA -PNEUMATIC DILATATION 7618
CM0904 : LAP FUNDOPLICATIONS 32805
CM0905-I : CYST EXCISION WITH OR WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 32805
CM0907 : ENUCLEATION OF CYST 29160
CM0908A-I : OTHER BYPASS PANCREAS 29160
CM0908B-I : TRIPLE BYPASS 29160
CM0910 : PANCREATIC NECROSECTOMY OPEN 30618
CM0911 : PANCREATIC NECROSECTOMY LAP 30618
CM0913 : SCLEROSING CHOLANGITIS 7290
CM0916 : AV FISTULA ( INCLUDING PRE TRANSPLANTATION ) 6926
CM0917 : COMPLEX AV ACCESS WITH GRAFT FOR HEMODIALYSIS 20777
CM0918 A : URETEROSCOPY AND DJ STENTING U/L 4374
CM0918 B : URETEROSCOPY AND DJ STENTING B/L 6561
CM0919 : URETEROSCOPY AND DJ STENT REMOVAL 2187
CM0920 : TRANSURETHRAL RESECTION OF BLADDER TUMOR /RE-TURBT 21870
CM0921A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - OPEN 10935
CM0921B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - OPEN 25515
CM0921C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - OPEN 11664
CM0921D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - OPEN 14580
CM0921E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - OPEN 29160
CM0921F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - OPEN 14580
CM0922A : EPIGASTRIC HERNIA / ABDOMINAL /UMBILICAL / FEMORAL HERNIA-WITHOUT MESH - LAP 10935
CM0922B : HIATUS HERNIA REPAIR ABDOMINAL - WITHOUT MESH - LAP 25515
CM0922C : VENTRAL AND SCAR /SPIGELIAN/OBTURATOR/SCIATIC- WITHOUT MESH - LAP 11664
CM0922D : EPIGASTRIC HERNIA/UMBILICAL HERNIA - WITH MESH - LAP 14580
CM0922E : HIATUS HERNIA REPAIR ABDOMINAL - WITH MESH - LAP 29160
CM0922F : VENTRAL AND SCAR / FEMORAL /SPIGELIAN/OBTURATOR/SCIATIC WITH MESH - LAP 14580
CM0924 : APPENDICULAR PERFORATION 10935
CM0925A : VAGOTOMY ANY TYPE WITHOUT DRAINAGE PROCEDURES 18225
CM0925B : VAGOTOMY ANY TYPE WITH DRAINAGE PROCEDURES 29160
CM0926 : OPERATION FOR BLEEDING PEPTIC ULCER 29160
CM0927 : PYLOROMYOTOMY 16038
CM0928 : OPERATIONS FOR RECURRENT INTESTINAL OBSTRUCTION (NOBLE PLICATION /OTHER) 25515
CM0929 : OPERATION FOR ACUTE INTESTINAL PERFORATION / PERFORATION PERITONITIS (INTESTINAL/GASTRIC/BILIARY)/ DUODENAL PERFORATION 21870
CM0930 : OPERATION FOR ACUTE INTESTINAL OBSTRUCTION (INCLUDING VOLVULUS / MALROTATION/INTUSUSCEPTION) 29160
CM0931-I : INVESTIGATION AND MANAGEMENT CHRONIC HEPATITIS B / C 158697
CM0932-I : CIRRHOSIS OF LIVER WITH COMPLICATIONS 21928
CM0935 : STAY IN GENERAL WARD - OBSERVATION FOR TRAUMA - PER DAY 510
CM0936 B : STAY IN ICU - MILD WITHOUT VENTILATION (FOR TRAUMA) 729
CM0936 C : STAY IN ICU - MODERATE WITHOUT VENTILATION (FOR TRAUMA) 10935
CM0936 D : STAY IN ICU - MODERATE WITH VENTILATION (FOR TRAUMA) 18225
CM0936 E : STAY IN ICU - SEVERE WITHOUT VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / coma) 18225
CM0936 F : STAY IN ICU - SEVERE WITH VENTILATION (FOR TRAUMA / POST OP COMPLICATIONS - Sepsis / Coma) 36450
CM0937 A : PYELOLITHOTOMY - OPEN 18225
CM0937 B : PYELOLITHOTOMY - LAP 18225
CM0938 A : NEPHROLITHOTOMY - OPEN 18225
CM0938 B : NEPHROLITHOTOMY - LAP 18225
CM0939 : OPEN CYSTOLITHOTOMY 10206
CM0940 A : URETEROLITHOTOMY - OPEN 14580
CM0940 B : URETEROLITHOTOMY - LAP 14580
CM0941 A : VESICOLITHOTOMY - OPEN 10206
CM0941 B : VESICOLITHOTOMY - LAP 10206
CM0952A-I-i-a : Imatinib 1525
CM0952A-I-i-b : Nilotinib 17800
CM0952A-I-ii-a : Induction 12840
CM0952A-I-ii-b : Imatinib 1525
CM0952A-I-ii-c : Nilotinib 17800
CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine 12320
CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine 10365
CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-I-iii-f : Idarubicin + Cytarabine 23240
CM0952A-I-iii-g : mitoxantrone + Cytarabine 10820
CM0952A-I-iii-h : Imatinib 1525
CM0952A-I-iii-i : Nilotinib 17800
CM0952A-I-iii-ii : Other Regimen 10000
CM0952A-I-iii-iii : Other Regimen 10000
CM0952A-II-a : Daunorubicin + Cytarabine 1 12320
CM0952A-II-b : Idarubicin + Cytarabine 23240
CM0952A-II-c : Daunorubicin + Cytarabine 2 10365
CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) 16725
CM0952A-II-e : Idarubicin + Cytarabine (High Dose) 29600
CM0952A-II-f : Daunorubicin (90mg) + Cytarabine 12320
CM0952A-II-g : idarubicin + Cytarabine 23240
CM0952A-II-h : mitoxantrone + Cytarabine 10280
CM0952A-II-i : Cytarabine 6800
CM0952A-II-j : Decitabine 25000
CM0952A-II-k : azacytidine 77500
CM0952A-II-l : Hydroxyurea 1600
CM0952A-II-m : Cytarabine - High Dose 9720
CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf 85150
CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf 40690
CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf 66710
CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone 13260
CM0952A-II-r : Cytarabine SC 2800
CM0952A-II-s : azacytidine 77500
CM0952A-II-t : Decitabine 25500
CM0952A-II-u : Other Regimen 10000
CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 1084
CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 25584
CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 32984
CM0952A-III-a-iv : Maintanance - Rituximab 25500
CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: 100500
CM0952A-III-c : Chlorambucil 2344
CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) 36500
CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) 37900
CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) 12500
CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) 6500
CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) 31898
CM0952A-III-f : Fludarabine + rituximab (FR) 67930
CM0952A-III-g : Alemtuzumab + rituximab 108950
CM0952A-III-h : Alemtuzumab without rituximab 11450
CM0952A-III-i : High-dose methylprednisolone + rituximab 103955
CM0952A-III-j : High-dose methylprednisolone 6455
CM0952A-III-k : Other Regimen 10000
CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE 13340
CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 17095
CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 19175
CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION 25291
CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION 41425
CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) 35621
CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) 12836
CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15133
CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 8460
CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3700
CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 3410
CM0952A-IV-i-c-5 : Imatinib 1525
CM0952A-IV-i-c-6 : Nilotinib 17800
CM0952A-IV-i-d : Other Regimen 10000
CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 62380
CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 11469
CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 13420
CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II 15133
CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III 5535
CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance 9923
CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE 15573
CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I 12110
CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II 3200
CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE 6410
CM0952A-IV-ii-b-5 : Imatinib 1525
CM0952A-IV-ii-b-6 : Nilotinib 17800
CM0952A-IV-ii-c : Corticosteroids + TKIs 9035
CM0952A-IV-ii-d : Other Regimen 10000
CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION 15678
CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE 28760
CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION 30779
CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) 15495
CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) 27210
CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance 56898
CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: 21155
CM0952A-IV-iii-v : CCG-1961 18310
CM0952A-IV-iii-vi : Other Regimen 10000
CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION 18038
CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION 16685
CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 60970
CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 56820
CM0952A-IV-iii-c : Other Regimen 10000
CM0953A-I-a : ABVD 4480
CM0953A-I-b : Escalated BEACOPP 7119
CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) 28480
CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD 102480
CM0953A-I-d-ii : ABVD 4480
CM0953A-I-e-i : CHOP + Rituximab 26818
CM0953A-I-e-ii : CHOP 2818
CM0953A-I-f-i : CVP +/- Rituximab 25768
CM0953A-I-f-ii : CVP 1768
CM0953A-I-g : Rituximab 25500
CM0953A-I-h : Other Regimen 10000
CM0953A-II-a : Bortezomib + dexamethasone 68038
CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab 26818
CM0953A-II-c : Rituximab 25500
CM0953A-II-d : Rituximab + cyclophosphamide + prednisone 25738
CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone 25520
CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) 2540
CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) 6000
CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) 6000
CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 24000
CM0953A-II-g-i : Bendamustine with or without rituximab 36500
CM0953A-II-g-ii : Bendamustine - rituximab 12500
CM0953A-II-h-i : Cladribine with or without rituximab 32250
CM0953A-II-h-ii : Cladribine - rituximab 8250
CM0953A-II-i : Bendamustine 12500
CM0953A-II-j : Chlorambucil 1126
CM0953A-II-k : Fludarabine 12030
CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) 32398
CM0953A-II-m : Alemtuzumab 2650
CM0953A-II-n : Other Regimen 10000
CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: 8967
CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: 66113
CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: 33108
CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: 36413
CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab 46780
CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) 32972
CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 46780
CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab 42847
CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) 32994
CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) 43894
CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) 32255
CM0953A-III-i-i : HDAC + Rituximab 27800
CM0953A-III-i-ii : Other Regimen 10000
CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) 4580
CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) 2100
CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-ii-c : CHOEP 8640
CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) 6892
CM0953A-III-ii-e : Other Regimen 10000
CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab 26818
CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iii-f : Other Regimen 10000
CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab 2500
CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 46780
CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) 42847
CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) 32972
CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) 32572
CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) 59429
CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) 61880
CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) 10969
CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) 12920
CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-iv-f : Other Regimen 10000
CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-v-b : Rituximab 25500
CM0953A-III-v-c : Other Regimen 10000
CM0953A-III-vi-a-1 : Bendamustine with or without rituximab 36500
CM0953A-III-vi-a-2 : Bendamustine (-) rituximab 12500
CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab 26818
CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) 2818
CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) 25768
CM0953A-III-vi-d : Rituximab 25500
CM0953A-III-vi-e : Lenalidomide + Rituximab 4940
CM0953A-III-vi-f : Other Regimen 10000
CM0953A-III-vii-a : SMILE 27483
CM0953A-III-vii-b : DeVIC +RT 9163
CM0953A-III-vii-c : VIPID 6619
CM0953A-III-vii-d : Other Regimen 10000
CM0954-i-a : Lenalidomide 2575
CM0954-ii-a-1 : rHu-Epo with or without G-CSF 26080
CM0954-ii-a-2 : rHu-Epo (-) G-CSF 25750
CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF 9330
CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF 9000
CM0954-iii-a-1 : Decitabine (15mg/m2) 15500
CM0954-iii-a-2 : Decitabine (20mg/m2) 16500
CM0954-iii-b : Lenalidomide 2575
CM0955-a : Lenalidomide (28 days) + Dexamethasone 6817
CM0955-b : Lenalidomide (21 days) + Dexamethasone 5004
CM0955-c : Lenalidomide 2575
CM0955-d : Bendamustine + Lenalidomide + Dexamethasone 13639
CM0955-e : Bendamustine 22000
CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone 5136
CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) 5764
CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) 7724
CM0955-i : High-dose Cyclophosphamide 5140
CM0955-j : VAD / VAMP 6104
CM0955-k : Melphalan 3900
CM0955-l : Melphalan + Prednisolone 1137
CM0955-m : Thalidomide + Dexamethasone 2376
CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) 2257
CM0959 : CYSTIC FIBROSIS 26681
CM0960 : SEPTIC SHOCK (ICU MANAGEMENT) 31383
CM0962-I : NEPHROTIC SYNDROME 11733
CM0963-I : NEPHROTIC SYNDROME WITH COMPLICATIONS 18950
CM0964-I : ACUTE DISSEMINATED ENCEPHALOMYELITIS 36450
CM0967-I : TOXIC/DRUG INDUCED LIVER INJURY 19537
CM0968 : MALIGNANT ASCITES 4119
CM0969 : SACROSPINOUS FIXATION (VAGINAL ROUTE) 16803
CM0973 : ENDOSCOPIC PARATHYROIDECTOMY 21870
CM0974-II : IVC FILTER REMOVAL 22125
CM0979-I : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS 51577
CM0980-I : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) 95681
CM0981 : LUDWIGS ANGINA AND OTHER NECK ABSCESS DRAINAGE 8748
CM0982 : OP /ANY POISIONING - CONSERVATIVE MANAGEMENT OR WITHOUT VENTILATORY SUPPORT (ONLY WITH FIR ) 13122
CM0985 : CRANIOFACIAL RESECTION 35247
CM0987 : ACUTE SEVERE ASTHMA WITH VENTILATION 37325
CM0988 : CRITICAL CARE ICU MANAGEMENT ( RESPIRATORY DISTRESS/ METABOLIC COMA/MULTIORGAN DYSFUNCTION/SEPTIC SHOCK/OTHERS WITH VENTILATION 22050
CM0989A : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (heparinisation) 14580
CM0989B : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (SK) 18225
CM0989C : CRITICAL CARE ICU MANAGEMENT -CRITICAL LIMB ISCHEMIA (rTPA) 54675
FUP0047A : ALL - First Qtr 1000
FUP0047B : ALL - Next 3 Qtrs 750
FUP0048A : CML - First Qtr 1000
FUP0048B : CML - Next 3 Qtrs 750
FUP0049A : CLL - First Qtr 1000
FUP0049B : CLL - Next 3 Qtrs 750
FUP0050A : MYELODYSPLASTIC SYNDROME - First Qtr 1000
FUP0050B : MYELODYSPLASTIC SYNDROME - Next 3 Qtrs 750
FUP0051A : LYMPHOMA HODGKIN DISEASE - First Qtr 1000
FUP0051B : LYMPHOMA HODGKIN DISEASE - Next 3 Qtrs 750
FUP0052A : LYMPHOMA NON HODGKINS DISEASES - First Qtr 1000
FUP0060A : UPTO-60% WITH SCALDS (CONSERVATIVE) - First Qtr 750
FUP0060B : UPTO-60% WITH SCALDS (CONSERVATIVE) - Next 3 Qtrs 500
FUP0061A : UP TO-60% MIXED BURNS (WITH SURGERIES) - First Qtr 750
FUP0061B : UP TO-60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs 500
FUP0062A : ABOVE 60% MIXED BURNS (WITH SURGERIES) - First Qtr 750
FUP0062B : ABOVE 60% MIXED BURNS (WITH SURGERIES) - Next 3 Qtrs 500
FUP0069A : INBORN ERROR OF METABOLISM - First Qtr 3000
FUP0069B : INBORN ERROR OF METABOLISM - Next 3 Qtrs 1500
FUP0070A : PRIMARY IMMUNO DEFICIENCY DISORDERS - First Qtr 1500
FUP0070B : PRIMARY IMMUNO DEFICIENCY DISORDERS - Next 3 Qtrs 1000
FUP0071A : HYPOPLASTIC/APLASTIC ANEMIA (FANCONI ANEMIA) - First Qtr 900
FUP0071B : HYPOPLASTIC/APLASTIC ANEMIA (FANCONI ANEMIA) - Next 3 Qtrs 500
FUP0075A : ECMO-EXTRACORPOREAL MEMBRANE OXYGENATION - First Qtr 3000
FUP0076B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0077A : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - First Qtr 1800
FUP0077B : MULTI SYSTEM ORGAN FAILURE- WITH OR WITHOUT /ARDS/DIC(BLOOD PRODUCTS) - Next 3 Qtrs 1000
FUP0092A : D V T - IVC FILTER - First Qtr 3500
FUP0092B : D V T - IVC FILTER - Next 3 Qtrs 1500
FUP0093A : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - First Qtr 3500
FUP0093B : AORTO-BIILIAC-BIFEOMRAL BYPASS WITH VEIN / SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0094A : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0094B : AXILLO BIFEMORAL BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0095A : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - First Qtr 3500
FUP0095B : CAROTID ARTERY BYPASS WITH SYNTHETIC GRAFT - Next 3 Qtrs 1500
FUP0096A : NECK VASCULAR INJURY - CAROTID VESSELS - First Qtr 3500
FUP0096B : NECK VASCULAR INJURY - CAROTID VESSELS - Next 3 Qtrs 1500
FUP0097A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - First Qtr 3500
FUP0097B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Next 3 Qtrs 1500
FUP0098A : THORACIC VASCULAR INJURIES - First Qtr 3500
FUP0098B : THORACIC VASCULAR INJURIES - Next 3 Qtrs 1500
FUP0101A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 1000
FUP0101B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 500
FUP0102A : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - First Qtr 2500
FUP0102B : PPH SURGICAL MANAGEMENT - HYSTERECTOMY/LIGATION/ EMBOLIZATION - Next 3 Qtrs 1000
FUP0103A : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - First Qtr 2500
FUP0103B : THALASSEMIA MAJOR/HAEMOGLOBINOPATHIES/ CHELATION THERAPY/SICKLE CELL ANAEMIA - Next 3 Qtrs 2500
FUP0106A : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - First Qtr 2500
FUP0106B : ACUTE PANCREATITIS - CONSERVATIVE MANAGEMENT / MILD / MODERATE / SEVERE MEDICAL / IMAGE GUIDED DRAINAGE OF PANCREATIC COLLECTIONS - Next 3 Qtrs 1500
FUP0109A : GROWTH HORMONE FOR HYPOPITUTARISM - First Qtr 3500
FUP0109B : GROWTH HORMONE FOR HYPOPITUTARISM - Next 3 Qtrs 1500
FUP0118A : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - First Qtr 2200
FUP0118B : THORACO ABDOMINAL ANEURYSM REPAIR WITH RENO / MESENTRIC REVASCULARISATION - Next 3 Qtrs 1000
FUP0135A : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - First Qtr 2000
FUP0135B : CHEMO EMBOLIZATION FOR LIVER TUMORS USING DRUG AND PVA OR DC BEADS - Next 3 Qtrs 1000
FUP0136A : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - First Qtr 3500
FUP0136B : TRANS JUGULAR INTRAHEPATIC PORTO SYSTEMIC SHUNT (TIPSS) - Next 3 Qtrs 1500
FUP0152A : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - First Qtr 2500
FUP0152B : VISCERAL ARTERY ANEURSYM REPAIR / RENAL ARTERY ANEURYSM REPAIR - Next 3 Qtrs 1500
FUP0153A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - First Qtr 2500
FUP0153B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - UNILATERAL - Next 3 Qtrs 1200
FUP0154A : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - First Qtr 2000
FUP0154B : HYBRID / OPEN INCLUDING COVERED STENT PLACEMENT - BILATERAL - Next 3 Qtrs 2000
CM0100-N : BREAST CANCER - TAMOXIFEN 100
CM0100-O : BREAST CANCER - AROMATASE INHIBITORS 1000
CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis 2700
CM0955-O : Multiple Myeloma - Zoledronic Acid 2700
CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles 7000
CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles 3500
CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy 9800
CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days 18400
CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) 15100
CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles 1800
CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 9200
CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. 4600
CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. 6000
CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. 4600
CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV 11100
CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) 7200
CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles 2100
CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. 66750
CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. 29250
CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. 66250
CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily 37250
CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily 3400
CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily 19250
CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily 3650
CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) 10000
CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles 8000
CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. 6500
CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles 7700
CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease 7200
CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. 5250
CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. 8000
CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. 6450
CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles 8700
CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated 5040
CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. 3820
CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. 7050
CM0694-II-d : ERCP and Stent (plastic) 18225
CM0694-II-e : ERCP and Stent (SEMS) 40095
CM0694-II-f : POST OP BILIARY STRICTURE 25515
CM0707-I-A : ACUTE MILD PANCREATITIS - CONSERVATIVE MANAGEMENT 21870
CM0707-I-B : ACUTE MODERATE PANCREATITIS - CONSERVATIVE MANAGEMENT 29160
CM0707-I-C : ACUTE SEVERE PANCREATITIS - CONSERVATIVE MANAGEMENT 40788
CM0630 B -II-c : MIXED CONNECTIVE TISSUE DISEASE - WITH GANGRENE ON IV PROSTACYCLIN 5103
CM0630 B -II-d : MIXED CONNECTIVE TISSUE DISEASE - PNEUMOCOCCAL VACCINATION 3645
CM0631A-II -a : VASCULITIS - PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE 2187
CM0631A-II -b : VASCULITIS - PULSE CYCLOPHOSPHAMIDE THERAPY 2187
CM0630 A-I-a-ii : MIXED CONNECTIVE TISSUE DISEASE- PULSE CYCLOPHOSPHAMIDE THERAPY 2187
CM0630 A-I-b-ii :MIXED CONNECTIVE TISSUE DISEASE-METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE 2187
CM0630 B -II-a : MYCOPHENOLATE MOFETIL INDUCTION 4374
CM0630 B -II-b : MYCOPHENOLATE MOFETIL MAINTENANCE 2187
CM0630 B -II-e : MIXED CONNECTIVE TISSUE DISEASE-(METHOTREXATE OR AZATHIOPRINE OR HYDROXY CHLOROQUINE/ PULSE CYCLOPHOSPHAMIDE THERAPY/ MYCOPHENOLATE MOFETIL INDUCTION/MYCOPHENOLATE MOFETIL MAINTENANCE/ WITH GANGRENE ON IV PROSTACYCLIN/ PNEUMOCOCCAL VACCIN 21870
CM0631A-II-c : VASCULITIS (PREDNISOLONE OR METHOTREXATE OR AZATHIOPRINE/ PULSE CYCLOPHOSPHAMIDE THERAPY )(including Diagnostic evaluation - 1st time) 8748
CM0707-II-A : ACUTE MILD PANCREATITIS - CONSERVATIVE MANAGEMENT 21870
CM0707-II-B : ACUTE MODERATE PANCREATITIS - CONSERVATIVE MANAGEMENT 29160
CM0707-II-C : ACUTE SEVERE PANCREATITIS - CONSERVATIVE MANAGEMENT 40788
CM0881 A-I-a : THALASSEMIA MAJOR (upto) 5103
CM0931-I-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS 1800
CM0931-I-C : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 0.5MG 30 TABS 3500
CM0931-I-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS 2000
CM0931-I-H : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + VELPATASVIR 100 28 TABS 6000
CM0931-II-B : MANAGEMENT CHRONIC HEPATITIS B / C - ENTECAVIR 1 MG 30 TABS 4500
CM0931-II-D : MANAGEMENT CHRONIC HEPATITIS B / C - TELBUVUDINE 600MG 30 TABS 16000
CM0931-II-F : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS 11000
CM0931-I-ii : INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) 10000
CM0931-II-I : MANAGEMENT CHRONIC HEPATITIS B / C - SOFOSBUVIR 400 MG 28 TABS + LEDIPASVIR 90 28 TABS 15000
CM0931-II-i i: INVESTIGATION OF CHRONIC HEPATITIS B / C (VIRAL LOAD) 10000
CM0931-I-J : MANAGEMENT CHRONIC HEPATITIS B / C INTERFERON WILL BE APPROVED BASED ON DOSAGE) 1000
CM0879-I-a :LAPAROSCOPIC - ECTOPIC RESECTION 15565
CM0629-II-a : OBSCURE BLEED - Conservative management including Capsule endoscopy 21870
CM0629-II-b : OBSCURE BLEED - Conservative 7290
CM0629-II-c : NON VARICEAL BLEED - CLIPPING 21870
CM0629-II-d : NON VARICEAL BLEED - ARGON PLASMA COAGULATION 33644
CM0629-II-e : NON VARICEAL BLEED - CONSERVATIVE 7290
CM0774 A : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 14616
CM0820-I-A : Amputation of AK / BK 21870
CM0820-I-B : Amputation of AE / BE 18225
CM0820-I-C : Amputation of Fore-Foot 10935
CM0820-I-E : Amputation of Toes 5103
CM0820-I-F : Amputation of Fingers 7290
CM0820-I-G : Trans Meta-Tarsal Amputation 10935
CM0879-I-b :LAPROTOMY - ECTOPIC RESECTION 8748
CM0898 A : COLONIC PULL THROW 36450
CM0898 B : COLOPLASTY 21870
CM0898 C : ABDOMINAL RESECTION 29160
CM0905-IA : CYST EXCISION WITH HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 32805
CM0905-IB : CYST EXCISION WITHOUT HEPATIC JEJUNOSTOMY/ BILIARY DRAINAGE 25515
CM0774 B : LAPROSCOPIC ASSISTED VAGINAL HYSTERECTOMY 14616
CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen 10000
CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen 10000
CM0212-A : HYPOPLASTIC ANEMIA 2260
CM0212-B : APLASTIC ANEMIA 2260
CM0212-C : FANCONI ANEMIA 2260
CM0213-A : NECROTISING ENTEROCOLITIS - NON VENTILATED 14580
CM0715A : CLEFT LIP - Unilateral 7290
CM0715B : CLEFT LIP - Bilateral 11737
CM0718A-II : MICROTIA/ANOTIA - STAGE 1 7290
CM0718A-IV : MICROTIA/ANOTIA - STAGE 1 (with artificial Implant) 18517
CM0158- a : Medical management only (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) upto 3645
CM0158- b : 10 to 20% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application 7290
CM0158- c : 20 to 30% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application 13851
CM0158- d : 30 to 40% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay 20412
CM0158- e : upto 10% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay 5103
CM0159 - b : 20 to 30% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG 21870
CM0159- a : UPTO 20% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG 14580
CM0159- c : 30 to 40% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay 29160
CM0160A : 40 TO 50% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application 36305
CM0161A : 40 to 50% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG 44469
CM0162A : 50 TO 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application including ICU stay 54530
CM0163- a : 50 TO 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay 59049
CM0164-a : ABOVE 60% burns (approval will be based on the area of burns as per clinical Photograph, Diagrammatic representation may be accepted for private parts) Medical management + collagen application + Surgical Treatment SSG including ICU stay 72900
CM0165a : Fingers 2916
CM0165b : Neck - MILD (LESS THAN 1/3RD) - Flexion and extension videos to be uploaded 10935
CM0165c : Others (elbow, thigh, etc) 7290
CM0165d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon 4374
CM0166a : Fingers 4374
CM0166b : Neck - MODERATE (1/3RD TO 2/3RD) - Flexion and extension videos to be uploaded 18225
CM0166c : Others (elbow, thigh, etc) 10935
CM0166d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon 4374
CM0167a : Fingers 5832
CM0167b : Neck - SEVERE (> 2/3RD) - Flexion and extension videos to be uploaded 24057
CM0167c : Others (elbow, thigh, etc) 14580
CM0167d : Pressure Garments and Physiotherapy (2 weeks) - only as an addon 4374
CM0168a : PTOSIS Single 10935
CM0168b : PTOSIS Bilateral 17861
CM0175a : Polydactyly - Simple 3645
CM0175b : Polydactyly - Bone and neurovascular bundle 7290
CM0175c : Simple syndactyly (per finger) 4374
CM0175d : Complex syndactyly (per finger) 7290
CM0175e : Radial clubhand 10935
CM0175f : Ulnar clubhand 10935
CM0175g : Macrodactyly 12758
CM0175h : Others minor (will be paid as per procedure) Upto 7290
CM0175i : Others major (will be paid as per procedure) Upto 19392
CM0176a : PRESSURE SORE RECONSTRUCTIVE SURGERY - SSG - per 10 sq CM (upto) 8748
CM0176b : PRESSURE SORE RECONSTRUCTIVE SURGERY - Single Rotation FLAP - per 10 sq CM (upto) - per 10 sq CM (upto) 10935
CM0176c : PRESSURE SORE RECONSTRUCTIVE SURGERY - Bilateral FLAP - per 10 sq CM (upto) 14580
CM0176d : PRESSURE SORE RECONSTRUCTIVE SURGERY - Musculocutaneous flap - per 10 sq CM (upto) 21870
CM0176e : PRESSURE SORE RECONSTRUCTIVE SURGERY - Fasciocutaneous flap - per 10 sq CM (upto) 18225
CM0176f : PRESSURE SORE RECONSTRUCTIVE SURGERY - Tensor fascia lata flap - per 10 sq CM (upto) 32004
CM0176g : others (payable based on the procedure carried out) (upto) 32004
CM0177a : single closure 14580
CM0177b : Fascia Lata Graft 25515
CM0177c : Mesh Closure 18225
CM0177d : Local Flaps 14580
CM0177e : Myocutaneous Transposition 25515
CM0177f : TRAM 32004
CM0178a : Unilateral 7290
CM0178b : Bilateral 11664
CM0716A : CLEFT PALATE - Partial 10935
CM0716B : CLEFT PALATE - Complete 14653
CM0716C : CLEFT PALATE - Sub mucous (before 1.5 years of age) 14653
CM0717A : Simple syndactyly (Per finger) 4374
CM0717B : Complex Syndactyly (Per finger) 7290
CM0717C : Simple syndactyly (Per finger) 10935
CM0717D : Complex Syndactyly (Per hand) 19392
CM0718A-I : MICROTIA/ANOTIA - STAGE 1 18517
CM0718A-III : MICROTIA/ANOTIA - STAGE 1 (with cartilage autograft) 10935
CM0722-III-A : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MAXILLA 7309
CM0722-III-B : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE 7309
CM0722-III-C : RECONSTRUCTIVE SURGERY FOLLWING FACIO MAXILLARY TRAUMA, FRACTURE MANDIBLE, MAXILLA- INTERDENTAL WIRING / Archbar 3645
CM0814-II-a : VASCULAR MALFORMATIONS- Sclerotherapy 9477
CM0814-II-b : VASCULAR MALFORMATIONS- Sclerotherapy and Excision 19137
CM0816A-i : FLAP SURGERIES CUTANEOUS- UPPER LIMB 14580
CM0816A-ii : FLAP SURGERIES CUTANEOUS- LOWER LIMB 8748
CM0338-A : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) < 3 sq CM Surface Area 10935
CM0338-B : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Limbs) 3 to 6 CM 14580
CM0338-C : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) < 3 CM 18225
CM0338-D : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Others) 3 to 6 CM 21870
CM0338-E : EXCISION OF ARTERIO VENOUS MALFORMATION - SMALL (Brain) < 6 CM 28978
CM0339-A : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Brain) > 6 CM 53946
CM0339-B : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Limbs) > 6 CM 18225
CM0339-C : EXCISION OF ARTERIO VENOUS MALFORMATION - LARGE (Others) > 6 CM 29160
CM0343-A : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Radial, cephalic, brachial, etc) - Repair 25515
CM0343-B : MEDIUM SIZE ARTERIAL ANEURYSMS (eg. Carotid, Jugular, Femoral, etc) - Repair 33899
CM0344-A : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT (eg. Radial, cephalic, brachial, etc) 43740
CM0344-B : MEDIUM SIZE ARTERIAL ANEURYSMS WITH SYNTHETIC GRAFT(eg. Carotid, Jugular, Femoral, etc) 53582
CM0347A-i : AORTO - ILLIAC BYPASS WITH VEIN 36450
CM0347A-ii : AORTO - FEMORAL BYPASS WITH VEIN 43740
CM0347B-i : AORTO - BILLIAC BYPASS WITH VEIN 51030
CM0347B-ii : AORTO - BIFEMORAL BYPASS WITH VEIN 57774
CM0347C-i : AORTO - ILLIAC BYPASS WITH SYNTHETIC GRAFT 51030
CM0347C-ii : AORTO - FEMORAL BYPASS WITH SYNTHETIC GRAFT 58320
CM0347D-i : AORTO - BILLIAC BYPASS WITH VEIN WITH SYNTHETIC GRAFT 59414
CM0347D-ii : AORTO - BIFEMORAL BYPASS WITH VEIN WITH SYNTHETIC GRAFT 67615
CM0367-A : VASCULAR INJURY IN UPPER LIMBS - AXILLARY REPAIR WITH VEIN GRAFT 24786
CM0367-B : VASCULAR INJURY IN UPPER LIMBS - BRACHIAL - REPAIR WITH VEIN GRAFT 18225
CM0367-C : VASCULAR INJURY IN UPPER LIMBS - RADIAL AND ULNAR - REPAIR WITH VEIN GRAFT 14580
CM0368A : MAJOR VASCULAR INJURY -REPAIR (Femoral) 30436
CM0368B : MAJOR VASCULAR INJURY -REPAIR (Tibial) 25515
CM0369A : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Fibular, Popliteal) 13305
CM0369B : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Foot) 8748
CM0369C : MINOR VASCULAR INJURY REPAIR -LOWER LIMBS (Digits) 5832
CM0373A : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Vein Graft 51030
CM0373B : ABDOMINAL VASCULAR INJURIES - AORTA, ILLAC ARTERIES, IVC, ILIAC VEINS - Synthetic Graft 66157
CM0375A : VARICOSE VEINS RFA FOR U/L 12758
CM0377C : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - STK 7290
CM0377D : THROMBOLYSIS FOR DEEP VEIN THROMBOSIS (Systemic) - RTPA 21870
CM0384A : PSEUDOANEURYSM LIGATION - Small vessels (eg. Radial, cephalic, brachial, etc) 10935
CM0384B : PSEUDOANEURYSM LIGATION - Medium vessels (eg. Carotid, Jugular, Femoral, etc) 21870
CM0384C : PSEUDOANEURYSM LIGATION - Large vessels (eg. Aorta, Iliac, IVC, etc) 25333
CM0384D : PSEUDOANEURYSM LIGATION -Post AV Fistula 8100
CM0395A : GRAFT THROMBECTOMY BYPASS 15492
CM0395B : AV ACCESS SURGERY (not for Dialysis) 10935
CM0674-II-a : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Balloon plasty 42465
CM0674-II-b : TIBIAL ANGIOPLASTY IN CRITICAL LIMB ISCHEMIA - Stenting 67980
CM0692-II-A : ACUTE STROKE THROMBOLYSIS (R TPA ) (Cathter Directed) 54858
CM0814-I-a : VASCULAR MALFORMATIONS- Sclerotherapy 9477
CM0814-I-b : VASCULAR MALFORMATIONS- Sclerotherapy and Excision 19137
CM1038 : Drainage of Subdiaphramatic Abscess 7290
CM1046 : Excision Benign Tumor -Small intestine 10935
CM1067 : IlieoSigmoidostomy 12393
CM1076 : Repair of Common Bile Duct 10935
CM1083 : Pharyngectomy& Reconstruction - Total 14580
CM1084 : Tracheoplasty (Throat) 10935
CM1088 : Estlander Operation (lip) 5103
CM1093 : Operation for carcinoma lip- cheek advancement 8748
CM1096 : Resection Enucleation of Adenoma (lung) 7290
CM1099 : Thoracoplasty 14580
CM1100 : Thoracoscopic Segmental Resection 18225
CM1101 : Thoracoscopic Sympathectomy 10935
CM1191 : Abdominal Perineal neo construction Cx + Uteria + Vagina 14580
CM1198 : Brust abdomen repair 10206
CM1212 : Intrauterine transfusions 7290
CM1231 : Endopyelotomy (retrograde with laser/bugbee) 18225
CM1232 : Endopyelotomy (antegrade with laser/bugbee) 20412
CM1233 : Ureterocalycostomy Open 18225
CM1234 : Ureterocalycostomy Laparoscopic 21870
CM1235 : Uretero-ureterostomy Open 18225
CM1236 : Uretero-ureterostomy Laparoscopic 25515
CM1252 : Holmium Laser Prostatectomy 29160
CM1313 : Operations for Congenital Arteriovenous Fistula 13500
CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage 30000
CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 15000
CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 25000
CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 50000
CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN 20000
CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month 3000
CM0692-II-B-i : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 50 mg) 30300
CM0692-II-B-ii : ACUTE STROKE THROMBOLYSIS (R TPA ) (IV - Thrombolysis - 70mg) 48300

Say hello to us , Toll-Free

1800 425 3993

Write to us

[email protected]
[email protected]

Reach us At

The Project Director

Tamil Nadu Health Systems Project (TNHSP)
3rd Floor, DMS Annex New Building
259 Anna Salai, Teynampet
Chennai - 600 006, Tamil Nadu.

CMCHIS Project Office

Chief Minister's Comprehensive Health Insurance Scheme
No.226,Om Sakthi Towers,
Kilpauk Garden Road, Kilpauk,
Chennai-600010, Tamil Nadu

Scan QR Code or Click Here to Download the Mobile app for Beneficiary

Visitors Count : 15071 / 25470599